SG11202107659SA - New recombinant diamine oxidase and its use for the treatment of diseases characterized by excess histamine - Google Patents
New recombinant diamine oxidase and its use for the treatment of diseases characterized by excess histamineInfo
- Publication number
- SG11202107659SA SG11202107659SA SG11202107659SA SG11202107659SA SG11202107659SA SG 11202107659S A SG11202107659S A SG 11202107659SA SG 11202107659S A SG11202107659S A SG 11202107659SA SG 11202107659S A SG11202107659S A SG 11202107659SA SG 11202107659S A SG11202107659S A SG 11202107659SA
- Authority
- SG
- Singapore
- Prior art keywords
- treatment
- diseases characterized
- new recombinant
- diamine oxidase
- excess histamine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
- C12N9/0014—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on the CH-NH2 group of donors (1.4)
- C12N9/0022—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on the CH-NH2 group of donors (1.4) with oxygen as acceptor (1.4.3)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/44—Oxidoreductases (1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/765—Serum albumin, e.g. HSA
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y104/00—Oxidoreductases acting on the CH-NH2 group of donors (1.4)
- C12Y104/03—Oxidoreductases acting on the CH-NH2 group of donors (1.4) with oxygen as acceptor (1.4.3)
- C12Y104/03022—Diamine oxidase (1.4.3.22)
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
- G16B30/20—Sequence assembly
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B35/00—ICT specially adapted for in silico combinatorial libraries of nucleic acids, proteins or peptides
- G16B35/10—Design of libraries
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Bioinformatics & Computational Biology (AREA)
- Evolutionary Biology (AREA)
- Medical Informatics (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Theoretical Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Library & Information Science (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Analytical Chemistry (AREA)
- Plant Pathology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP19157932 | 2019-02-19 | ||
PCT/EP2020/054197 WO2020169577A1 (en) | 2019-02-19 | 2020-02-18 | New recombinant diamine oxidase and its use for the treatment of diseases characterized by excess histamine |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202107659SA true SG11202107659SA (en) | 2021-09-29 |
Family
ID=65493995
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202107659SA SG11202107659SA (en) | 2019-02-19 | 2020-02-18 | New recombinant diamine oxidase and its use for the treatment of diseases characterized by excess histamine |
Country Status (12)
Country | Link |
---|---|
US (1) | US20220145269A1 (en) |
EP (1) | EP3927817A1 (en) |
JP (1) | JP2022520862A (en) |
KR (1) | KR20210132650A (en) |
AU (1) | AU2020225319A1 (en) |
BR (1) | BR112021015865A2 (en) |
CA (1) | CA3130751A1 (en) |
EA (1) | EA202192305A1 (en) |
IL (1) | IL285452A (en) |
MX (1) | MX2021010050A (en) |
SG (1) | SG11202107659SA (en) |
WO (1) | WO2020169577A1 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10894812B1 (en) | 2020-09-30 | 2021-01-19 | Alpine Roads, Inc. | Recombinant milk proteins |
AU2021353004A1 (en) | 2020-09-30 | 2023-04-13 | Nobell Foods, Inc. | Recombinant milk proteins and food compositions comprising the same |
US10947552B1 (en) | 2020-09-30 | 2021-03-16 | Alpine Roads, Inc. | Recombinant fusion proteins for producing milk proteins in plants |
WO2023235897A2 (en) * | 2022-06-03 | 2023-12-07 | Oyster Point Pharma. Inc. | Aav vector encoding diamine oxidase and uses thereof |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1317067B1 (en) | 2000-11-29 | 2003-05-26 | Univ Roma | HISTAMINAS OF VEGETABLE ORIGIN IN THE TREATMENT OF ESPECTIC ALLERGIC SHOCK AND ALLERGIC ASTHMA. |
AT502098B8 (en) | 2004-07-07 | 2007-06-15 | Albert Dr Missbichler | DIAMOND OXIDASE-CONTAINING COMPOSITION |
DK2611454T3 (en) | 2010-09-02 | 2015-06-29 | Naturland Magyarország Termelö És Kereskedelmi Kft | Orally usable preparation, containing vegetable origin histaminase resistant to pepsin and trypsin, and process for preparation thereof |
-
2020
- 2020-02-18 US US17/430,714 patent/US20220145269A1/en active Pending
- 2020-02-18 WO PCT/EP2020/054197 patent/WO2020169577A1/en unknown
- 2020-02-18 MX MX2021010050A patent/MX2021010050A/en unknown
- 2020-02-18 EP EP20704547.7A patent/EP3927817A1/en active Pending
- 2020-02-18 KR KR1020217024580A patent/KR20210132650A/en unknown
- 2020-02-18 BR BR112021015865-0A patent/BR112021015865A2/en unknown
- 2020-02-18 CA CA3130751A patent/CA3130751A1/en active Pending
- 2020-02-18 JP JP2021548232A patent/JP2022520862A/en active Pending
- 2020-02-18 SG SG11202107659SA patent/SG11202107659SA/en unknown
- 2020-02-18 AU AU2020225319A patent/AU2020225319A1/en active Pending
- 2020-02-18 EA EA202192305A patent/EA202192305A1/en unknown
-
2021
- 2021-08-08 IL IL285452A patent/IL285452A/en unknown
Also Published As
Publication number | Publication date |
---|---|
AU2020225319A1 (en) | 2021-10-14 |
EA202192305A1 (en) | 2021-12-08 |
CN113785052A (en) | 2021-12-10 |
EP3927817A1 (en) | 2021-12-29 |
JP2022520862A (en) | 2022-04-01 |
MX2021010050A (en) | 2021-09-21 |
CA3130751A1 (en) | 2020-08-27 |
US20220145269A1 (en) | 2022-05-12 |
BR112021015865A2 (en) | 2021-10-05 |
IL285452A (en) | 2021-09-30 |
WO2020169577A1 (en) | 2020-08-27 |
KR20210132650A (en) | 2021-11-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL285452A (en) | New recombinant diamine oxidase and its use for the treatment of diseases characterized by excess histamine | |
IL288214A (en) | Quinazolin-4-one derivatives useful for the treatment of braf-associated diseases and disorders | |
HUE058931T2 (en) | Use of pilocarpine hydrochloride for the treatment of presbyopia | |
EP4009948A4 (en) | Use of tgf-alpha polypeptide or anti-tgf-alpha antibodies for the treatment of diseases and disorders | |
SG11202011018PA (en) | 1,3-thiazol-2-yl substituted benzamides for the treatment of diseases associated with nerve fiber sensitization | |
IL284414A (en) | Methods and compositions for the treatment of fabry disease | |
SG11202011010YA (en) | 1,3-thiazol-2-yl substituted benzamides for the treatment of diseases associated with nerve fiber sensitization | |
IL288195A (en) | Use of cannabidiol in the treatment of epileptic spasms | |
IL287280A (en) | Compounds and methods for the treatment of ocular disorders | |
IL291735A (en) | Heteroaryl-biphenyl amines for the treatment of pd-l1 diseases | |
IL287796A (en) | Compositions and methods for the treatment of atpase-mediated diseases | |
IL289405A (en) | Personalized treatment of ophthalmologic diseases | |
EP4034109A4 (en) | Method and composition for the treatment of disease | |
IL284029A (en) | Peptides for treatment and prevention of diabetes and associated disorders | |
EP4010075A4 (en) | Methods for the treatment of apoc3-related diseases and disorders | |
PL3937948T3 (en) | Phytoecdysones and the derivatives thereof for use in the treatment of neuromuscular diseases | |
EP3955914A4 (en) | Novel compounds and methods of use treating fructose-related disorders or diseases | |
EP3744347A4 (en) | Composition for skin diseases treatment use | |
GB201805100D0 (en) | Treatment of sarcopenic diseases | |
IL289371A (en) | Methylthioninium for use in the treatment of synaptopathies | |
SG11202010034WA (en) | TREATMENT OF SKIN DISEASES OR DISORDERS BY DELIVERY OF ANTI-OSMRß ANTIBODY | |
GB2603379B (en) | Avocatin B for the treatment of diseases and conditions | |
GB2574747B (en) | Use of lambda interferons in the treatment of obesity-related disorders and related diseases | |
ZA202106250B (en) | Therapeutic uses of dulaglutide | |
GB201909438D0 (en) | Treatment of diseases |